Assess patient compliance with self-administration of subcutaneous low-molecular-weight-heparin (enoxaparin) injections for 14 days following knee replacement surgery. Consecutive patients undergoing knee replacement surgery during a 4-month period were identified from a database. All patients had been taught to self administer enoxaparin injections during their in patient stay and asked to self administer the remaining injections after discharge if feasible. Patients were then sent questionnaires designed to assess compliance.Objective
Methods
Patellofemoral replacement is an established intervention in selected patients with severe isolated patellofemoral osteoarthritis. FPV (Wright Medical, UK) is a third generation patellofemoral arthroplasty implant and is the second most used after AVON in National Joint Registry for England and Wales. Reports of survivorship and functional of this implant are scarce in literature. Evaluation of functional outcome and survivorship following FPV patellofemoral arthroplasty.Background
Aim
